Benjamin Looker Sells 11,824 Shares of Esperion Therapeutics (NASDAQ:ESPR) Stock

Posted by Brenda Bartman on Jun 18th, 2026

Esperion Therapeutics, Inc. (NASDAQ:ESPR – Get Free Report) insider Benjamin Looker sold 11,824 shares of the firm’s stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $3.15, for a total transaction of $37,245.60. Following the completion of the transaction, the insider directly owned 667,524 shares in the company, valued at approximately $2,102,700.60. The trade was a 1.74% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Esperion Therapeutics Price Performance

Shares of Esperion Therapeutics stock traded down $0.02 on Thursday, hitting $3.15. 17,492,649 shares of the company’s stock traded hands, compared to its average volume of 9,162,250. The firm’s 50-day moving average price is $2.75 and its two-hundred day moving average price is $3.12. The stock has a market capitalization of $811.72 million, a PE ratio of -52.50, a price-to-earnings-growth ratio of 2.57 and a beta of 1.07. Esperion Therapeutics, Inc. has a one year low of $0.95 and a one year high of $4.18.

Esperion Therapeutics (NASDAQ:ESPR – Get Free Report) last posted its quarterly earnings results on Friday, May 8th. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by ($0.08). Esperion Therapeutics had a negative return on equity of 0.14% and a net margin of 0.12%.The company had revenue of $80.10 million during the quarter, compared to the consensus estimate of $84.52 million.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of ESPR. Sivia Capital Partners LLC acquired a new position in shares of Esperion Therapeutics during the 2nd quarter worth approximately $25,000. R Squared Ltd bought a new position in shares of Esperion Therapeutics in the third quarter valued at $33,000. Kestra Advisory Services LLC bought a new position in shares of Esperion Therapeutics in the fourth quarter valued at $35,000. KFG Wealth Management LLC acquired a new position in Esperion Therapeutics during the fourth quarter worth $37,000. Finally, Cary Street Partners Financial LLC acquired a new position in Esperion Therapeutics during the fourth quarter worth $38,000. 47.39% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

ESPR has been the topic of several recent analyst reports. Citizens Jmp lowered shares of Esperion Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, May 1st. Jefferies Financial Group downgraded shares of Esperion Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, May 1st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Esperion Therapeutics in a research note on Tuesday, April 21st. Piper Sandler cut Esperion Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, May 1st. Finally, Needham & Company LLC downgraded shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, May 4th. One investment analyst has rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $5.54.

Get Our Latest Stock Analysis on Esperion Therapeutics

About Esperion Therapeutics

(Get Free Report)

Esperion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of oral, low–density lipoprotein cholesterol (LDL-C)–lowering therapies. The company’s research and development efforts center on small-molecule compounds designed to address atherosclerotic cardiovascular disease by targeting cholesterol biosynthesis pathways. Esperion seeks to provide novel treatment options for patients who require additional LDL-C reduction beyond what is achieved with statins or who are statin-intolerant.

The company’s lead products include NEXLETOL (bempedoic acid), an oral adenosine triphosphate–citrate lyase (ACL) inhibitor approved by the U.S.